Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.62, read 2026-11-03
Ethical does not pass the values gate
Price15.24 USD
Fair value11.26
Ethical score70.0/100
Value readOvervaluedas of 7 Nov 2026
Our investment reviews on this name
2026-10-28Read Distribution15.27-0.2% to today ✓Markdown gives way to Distribution after a 6% slide in 2 weeks
2026-10-11Read Markdown16.30-6.5% to today ✓Accumulation gives way to Markdown
2026-09-02Read Accumulation16.31-6.6% to today First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
National Healthcare Properties, Inc. holds its Markup at $15.24. Elevated stress, defensive posture warranted, held for 2 days.
As held on the ledger · 2026-11-07
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 2 days
Price at the screen
$15.24
Valuation
N/A trailing · 69.27 forward price to earnings
Values screen
FAIL· score 70.0
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
61.06%
Below 33%
Interest-bearing debt is 61.1% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.00%
Below 33%
Cash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.
Pass
Receivables
5.16%
Below 49%
Money owed to the company is 5.2% of assets, under the 49% limit.
Pass
Revenue purity
0.08%
Below 5%
Only 0.1% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
National Healthcare Properties,'s business is in a permissible area, but its interest-bearing debt is about 61% of the company, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-11-07. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when NHP's ethical verdict changes
Today NHP does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 7 Nov 2026: it trades above our $11.26 fair value estimate, 19.80% revenue growth.
Fair value range in USD, drawn from the 2026-11-07 screen. The gold marker is the market price at the same screen. The price runs 35.3% above the base estimate.
Third-party analyst targets. The average target sits +25% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Where our models see it going: fair-value estimate $11.26, with a range of $11.26 to $12.95, dated to the 2026-11-07 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Why it gives us pause
At 69.3x forward earnings, the price already runs ahead of the business. It trades 35% above our $11.26 fair value, so you would be buying at a premium, not a discount.
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
NHP trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-11-04Distribution$15.49+2.7%Entry 13
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 2.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-03Distribution$15.08+0.0%Entry 12
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-02Distribution$15.08+0.0%Entry 11
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-11-01Distribution$15.08-1.2%Entry 10
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 1.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-31Distribution$15.27+0.0%Entry 9
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-30Distribution$15.27+0.0%Entry 8
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Distribution$15.27+0.0%Entry 7
The analysis reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to distribution since the last review. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved up 4.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Markdown$14.67+0.0%Entry 5
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bearish. The street (7 analysts) rates it buy, with a mean price target of $17.
2026-10-18Markdown$14.67-10.0%Entry 4
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 10.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading bullish. The street (7 analysts) rates it buy, with a mean price target of $17.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.